Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer - TheStreet.com

TheStreet.com

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer TheStreet.com Merck's flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday. Adam Feuerstein. Follow. Jun 16 ... Merck (MRK) Announces Superior Data on KEYTRUDA vs. Chemotherapy in Untreated NSCLCStreetInsider.com Merck's stock surges on positive results from cancer-treatment studyMarketWatch Merck's Keytruda successful in late-stage lung cancer studySeeking Alpha all 7 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNHx-curImafEjSMjSnv-QZomRZAFA&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779134102740&ei=AqxiV_jpI8HbpwfulK8I&url=https://www.thestreet.com/story/13609867/1/merck-extends-cancer-immunotherapy-reach-to-first-line-lung-cancer.html
via IFTTT